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Abstract
Atrial fibrillation occurs frequently in medical intensive care unit
patients. Most intensivists tend to treat this rhythm disorder
because they believe it is detrimental. Whether atrial fibrillation
contributes to morbidity and/or mortality and whether atrial
fibrillation is an epiphenomenon of severe disease, however, are
not clear. As a consequence, it is unknown whether treatment of
the arrhythmia affects the outcome. Furthermore, if treatment is
deemed necessary, it is not known what the best treatment is. We
developed a treatment protocol by searching for the best evidence.
Because studies in medical intensive care unit patients are scarce,
the evidence comes mainly from extrapolation of data derived from
other patient groups. We propose a treatment strategy with
magnesium infusion followed by amiodarone in case of failure.
Although this strategy seems to be effective in both rhythm control
and rate control, the mortality remained high. A randomised
controlled trial in medical intensive care unit patients with placebo
treatment in the control arm is therefore still defendable.
Introduction
Atrial fibrillation (AF) is frequently observed in the medical
intensive care unit (MICU) [1], with up to about 15% of MICU
patients showing periods of AF [2-4]. AF directly leads to loss
of the atrial kick and, as a consequence, reduces ventricular
loading. Especially if the ventricular compliance is decreased,
as is the case in sepsis and many other medical conditions, this
reduction results in decreased cardiac performance. By
performance, we mean the capacity to meet pressure and
volume requirements. The irregular and mostly rapid ventricular
response also shortens the ventricular filling time, and thereby
shortens the preload. AF therefore reduces cardiac
performance. The reduction is more serious in patients with
pre-existing cardiac dysfunction due to decreased ventricular
compliance. A persistent high ventricular rate may lead to
tachycardia-mediated cardiomyopathy [5]. Conversion to sinus
rhythm (SR) improves ventricular function in patients with heart
failure [6]. These findings urge most intensivists to treat AF.
Most intensivists may have adopted an AF treatment modality
based on their individual experience combined with
extrapolation of the treatment of other, mostly unrelated, but
well-defined and well-established, patient groups. In most
cases this means that, after correction of assumed or
perpetuating factors, treatment directly aimed at the rhythm
disorder itself will be started. To date, treatment of AF in the
MICU cannot be supported by sufficient evidence from the
literature. Notwithstanding the large number of patients
involved, thorough research in this field is scarce [7]. There
are important reasons to believe that MICU patients are
different from other patients with AF and therefore require a
more tailored therapy. Fundamental questions that remain
unanswered for MICU patients are summarised in Table 1.
To find answers for these questions we searched for direct
clinical evidence and – when not available – searched for
evidence from related areas. Direct evidence will be
considered all results derived from randomised controlled
trials or well-conducted epidemiological studies in MICU
patients. The aim of the present paper is to improve insight, to
explore future research goals and to define an optimal
treatment mode based on current knowledge for the
population admitted in MICU. We will describe the evidence
found per question presented in Table 1 according to the
patient group from which it is derived. Each section will start
with MICU patients, followed by mixed intensive care unit
(ICU) patients, surgical ICU patients and cardiothoracic
surgery ICU patients, and will end with the least related
patient category – outpatients.
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Methodology
We conducted a computer literature search in the databases
of MEDLINE, EMBASE and the Cochrane Library, from 1966
to 2007, combining the following key words: ‘intensive care’
or ‘critical care’ or ‘critically ill’ and ‘atrial fibrillation’ or ‘atrial
tachyarrhythmia’ and ‘treatment’ or ‘aetiology’ or ‘risk factors’.
Reference lists of all selected articles were reviewed to
identify other relevant articles. For relevant articles the search
was extended in PubMed with the ‘related articles’ search
function. PubMed was checked for other publications by
authors of key papers. Web of Science® was checked for
papers citing key papers. All selected articles were reviewed
by two different reviewers.
Definitions
AF is a supraventricular tachyarrhythmia characterised by
uncoordinated atrial activation with subsequent deterioration
of atrial mechanical function. On the electrocardiogram, AF
is described by the replacement of consistent P waves with
rapid oscillations or fibrillatory waves that vary in size, shape
and timing, associated with an irregular, frequently rapid,
ventricular response when atrioventricular conduction is
intact [8]. Recurrent means at least two episodes of AF.
Paroxysmal means self-terminating, and persistent means
that self-termination is absent and that electrical or
pharmacological conversion is necessary to end AF [9].
MICU patients are patients admitted to the ICU not for
surgical or cardiological reasons.
What is the pathophysiology of atrial
fibrillation?
There are no data on MICU patients specifically, nor data for
surgical ICU patients. There are, however, risk factors
identified in these patient categories. Risk factors due to
causality can in general not be distinguished from
epiphenomena. Risk factors can at least suggest a certain
pathophysiology, however, and therefore they may help in the
identification of a patient population. Independent risk factors
for AF are age, disease severity, hypertension, hypoxia,
previous AF, congestive heart failure, chronic obstructive
pulmonary disease, chest trauma, shock, a pulmonary artery
catheter, previous use of calcium-channel blockers, low
serum magnesium, withdrawal of β-blocker or angiotensin-
converting enzyme-inhibitor and withdrawal of catecholamine
use [10-17].
In patients after noncardiac surgery, the right atrial pressure
rather than fluid overload or right heart enlargement seems to
be correlated with AF [14,18-20]. Cardiothoracic surgical
(CTS) patients with AF, however, tend to have a more
positive fluid balance [21,22]. Interestingly, systemic
inflammatory response syndrome and sepsis are also
independent risk factors [10,14]. A proinflammatory state, as
measured by leucocytosis or monocyte activation, is
associated with AF, although the mechanism is not clear [23-
25]. AF is sometimes the first sign of sepsis [4]. A genetic
predisposition for an increased inflammatory response is
associated with an increased incidence of postoperative AF
[26]. Catecholamines influence the susceptibility for AF
[10,27]. Hypovolaemia is also a risk factor [28].
Most knowledge about AF is gained from studies in
noncritically ill patients. AF is probably the final common
pathway of structural changes in combination with a trigger
leading to abnormal activation patterns in the atria [8].
Structural changes can be multiple; for example, fibrosis and
amyloidosis. Structural changes increase with age, which
might be the explanation for the fact that age is the most
important risk factor for AF. There are numerous triggers that
can lead to AF when combined with a substrate and a
perpetuating factor. Ischaemia, and local (pericarditis or
myocarditis) and generalised inflammation can affect the atria
[29,30]. Hypovolaemia and hypervolaemia or a sudden
increase in afterload, as in pulmonary embolism, and mitral or
tricuspid valve dysfunction are examples of increased atrial
workload that can cause AF. Nervous (both sympathic and
parasympathic) tone, hormonal changes, electrolyte distur-
bances and also the preload and the afterload influence
excitability and conduction in the atria and atrio–ventricular
junction [27]. The cumulative effect of structural changes and
one or more of these triggers and perpetuating factors will
determine whether AF will occur and will persist [8,31].
Conclusion on pathophysiology
From human and animal studies it is clear that the cause of AF
is multifactorial. There are more or less permanent changes in
morphology and more or less temporary changes in
haemodynamic balance, electrolyte balance, neural balance
and hormonal balance that facilitate an appropriate
environment and electrical stage for AF. Given the identified
risk factors it is clear that the population admitted to a MICU
Table 1
Questions regarding the prevalence and treatment of atrial
fibrillation in medical intensive care unit patients
What is the pathophysiology of atrial fibrillation in medical intensive
care unit patients? 
Does atrial fibrillation attribute to mortality?
Does atrial fibrillation attribute to morbidity?
Can atrial fibrillation be treated or prevented?
What are the adverse effects of any treatment?
Can (preventive) treatment of atrial fibrillation improve survival?
Can (preventive) treatment of atrial fibrillation improve morbidity?
Should we aim for rate control or rhythm control?
Does atrial fibrillation increase stroke incidence in medical intensive
care unit patients?
Can atrial fibrillation-associated stroke be prevented?Page 3 of 10
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differs in prevalence of risk factors, and therefore differs in AF
mechanism, from other ICU and non-ICU populations.
Especially inflammation, haemodynamic changes, increasing
age, comorbidity and neuroendocrine disturbances are more
frequent in MICU patients. Extrapolation of data from non-
MICU patients to MICU patients can only be done with caution.
Does atrial fibrillation attribute to mortality?
AF did not influence mortality significantly in a mixed
medical–cardiac ICU [2]. In a general ICU population,
however, patients with AF appeared to have a significantly
higher mortality compared with patients without AF [3].
Furthermore, surgical patients with new-onset AF have a
significantly higher disease severity and higher ICU mortality
[4,11,32,33]. A persistent elevated increased heart rate,
frequently due to AF, is associated with increased mortality
[34]. In a large, retrospective, cohort study in cardiac surgery
patients, AF was not an independent predictor for inhospital
mortality [35]. Patients outside the ICU setting with AF have
increased overall mortality and mortality of cardiovascular
causes [36,37].
Conclusion on mortality
There is an association between AF and mortality in some
patient groups. There is, however, no evidence for a causal
relationship [38]. Both AF and mortality being a result of
disease severity might be one of the explanations for the
association [10]. A causal mechanism they have in common
(for example, inflammation) might be another explanation.
Does atrial fibrillation attribute to morbidity?
AF did increase the length of stay (LOS) in a mixed medical–
cardiac ICU [2]. Onset of AF in a patient in the surgical ICU
increases their LOS in the ICU and in the hospital
[11,16,32,33,39,40]. Onset of AF reduces the systolic
blood pressure [41,42], and also decreases oxygen saturation
and increases the pulmonary artery wedge pressure. An
increased heart rate is associated with increased morbidity
[34].
A number of symptoms in noncritically ill patients have been
described [8]. Most relevant for ICU patients is the
decreased cardiac output, which is caused by the loss of
coordinated atrial contraction, by irregularity of ventricular
contraction [43], by inadequate filling time for the left
ventricle due to tachycardia, and by tachycardiomyopathy
[8,44]. Tachycardiomyopathy can occur as soon as 24 hours
after the start of AF [44].
Conclusion on morbidity
In all patient categories, AF is associated with increased
morbidity. This is reflected by the number of reported
symptoms and by the days spent in the ICU and in the
hospital. Haemodynamic parameters also tend to be worse in
patients with AF. As for mortality, the causality of increased
morbidity is hard to prove.
Can atrial fibrillation be prevented?
Although advocated in the early days of intensive care, there
is no evidence that digoxin or any other antiarrhythmic drug
can prevent AF in critically ill patients [41,45]. There are no
trials investigating prevention of AF in MICU patients.
In surgical ICU patients, and especially in CTS patients, there
are trials and guidelines evaluating preventive measures
[46,47]. Although prophylactic digoxin, verapamil and β-
blockers all decrease the heart rate in cases of postoperative
AF, only β-blockers decrease the incidence of postoperative
AF as shown in a meta-analysis [48]. In CTS patients, β-
blockers can reduce AF by 75% [12].
In randomised controlled trials, amiodarone prevented AF in
patients undergoing CTS, and also reduced the hospital LOS
and the ICU LOS [49-55]. There is no consensus, however,
about the clinical relevance of this finding since data are
conflicting [56,57]. Amiodarone, for example, was found to
increase the ICU LOS and the need for vasoactive
medication or other haemodynamic support in some studies
[13,58]. More recent meta-analyses show that amiodarone
prevents AF but the influence on the LOS or the mortality is
not yet unequivocally established [59,60].
Magnesium and atrial pacing cannot prevent AF in CTS
patients, as shown in several randomised controlled trials
[13,52,61,62]. In a comparative trial, however, magnesium
could prevent AF equally as effectively as sotalol; both drugs
combined had a synergistic effect [63]. Amiodarone and
magnesium are also synergistic [64], but synergism could
not be shown for propranolol and magnesium [65]. Recent
meta-analyses show that magnesium can prevent AF but
without any effect on the LOS or on the mortality [66,67].
Cholesterol synthesis inhibitors and corticosteroids also are
preventive, perhaps by interaction with inflammatory
pathways [68-70].
Studies on prevention have extensively been reviewed
recently [15,59,60,71]. Guidelines advise the prophylactic
use of β-blocker or amiodarone for elective CTS patients
[15,46,59,60]. Generalisation of prevention studies in CTS
patients to MICU patients is unproven.
Can atrial fibrillation be treated?
There are no randomised placebo-controlled trials in MICU
patients aimed at treating AF once it has occurred. There are,
however, comparative trials between drugs that are supposed
to be effective. Procainamide and amiodarone are equally
effective; after 12 hours, 70% of the patients were in SR
[72]. Magnesium, when compared with amiodarone, has
been found to be more effective in restoration of SR, while
the two treatments are equally effective in rate control [73].
Ibutilide, a relatively new class III agent, can restore SR in
70% of patients that fail rhythm control with amiodarone
treatment [74]. Ibutilide can restore SR – with 80%
Available online http://ccforum.com/content/11/6/233conversion to SR in haemodynamically unstable patients
without unmanageable proarrhythmic side effects [75].
In the CTS population, 80% of patients with AF convert to
SR within 24 hours. The use of β-blockers before the start of
AF and the absence of diabetes and left ventricular hyper-
trophy were independent predictors of conversion to SR [76].
In a retrospective study of surgical patients with new-onset
supraventricular tachycardia (93% with AF), 75% had SR
within 48 hours after the start of continuous infusion of
amiodarone [77]. In a mixed population with severe left
ventricular dysfunction, amiodarone had no apparent negative
effect on haemodynamics [78]. When compared with
amiodarone, propafenone gives earlier conversion to SR but
the ultimate conversion percentage was equal after CTS [79].
Ibutilide showed a dose-dependent conversion rate in a
randomised controlled trial [80]. Ibutilide and amiodarone
have an equal conversion rate to SR and an equivalent time
to conversion, but amiodarone causes more hypotension –
probably due to vasodilatation [81,82]. Direct-current
cardioversion has a low rate of conversion to SR in
postsurgical new-onset AF [10,83,84].
Treatment of AF in CTS patients has been the topic of several
reviews and guidelines [85,86]. The studies in these patients
are sufficiently powered to detect effectiveness for their
primary end point, prophylaxis or treatment of AF, but are
underpowered to detect differences in mortality or adverse
effects due to the low incidence of these events.
There are also studies in mixed ICU populations. Diltiazem
and amiodarone appeared equally effective in achieving rate
control; however, discontinuation of the study drug because
of hypotension occurred more often in the diltiazem group
[87]. Ibutilide is effective for rapid conversion, but with
potentially life-threatening proarrhythmic side effects [88].
Magnesium is more effective in rate control and probably in
conversion than diltiazem in a mixed population with
longstanding AF paroxysms [52]. With digoxin treatment, no
rate control or rhythm control can be reached in a mixed ICU
population [28,41]. The success rate of electric cardioversion
is also low in this population [28,41].
The management of AF in noncritically ill patients has been
studied and reviewed extensively [89,90]. New-onset AF has
a high spontaneous conversion rate of 64–90% within 24
hours [91]. Treatment with digoxin has been replaced by
treatment with β-blockers and calcium-channel blockers
because better rate control can be achieved with these latter
drugs. Especially in seriously ill patients, digoxin fails to
achieve an adequate reduction of the ventricular rate [92].
Class I and class III antiarrhythmic drugs are effective in
conversion of AF in recent-onset AF, especially when
combined with verapamil [89,90,93]. Amiodarone is also an
effective drug because high-dose oral or intravenous
amiodarone has a higher conversion ratio to SR than placebo
[91,94-97]. A meta-analysis showed that class IA, class IC
and class III antiarrhythmic agents are equally effective in
obtaining SR [98]. Meta-analyses comparing amiodarone
with class IC antiarrythmic drugs or placebo showed that
treatment was equally effective, although conversion was
earlier in class IC treatment [96,99]. None of the drugs was
associated with an increased or a decreased mortality [98].
Depending on the AF duration, amiodarone is highly effective
in conversion with no more adverse effects than other drugs
[100]. In patients with severe congestive heart failure,
amiodarone controls the heart rate immediately [101,102].
Magnesium is safe, reliable and cost-effective compared with
diltiazem [52]. Ibutilide is a safe and effective drug in
persistent AF [103]. Angiotensin-converting enzyme-inhibitors
might be effective in preventing structural changes (for
example, fibrosis) and might therefore enhance outcome in
AF patients, even in patients with worse underlying heart
disease [104]. Glucocorticoid therapy reduces the
proinflammatory state as measured by C-reactive protein and
probably, as a consequence, the incidence of AF [105].
Electrical cardioversion in noncritically ill patients is effective
but has a high relapse rate [8]. The timing of treatment is
important because applying electric cardioversion too early
leads to an increased recurrence of AF [106]. Whether the
findings in noncritically ill patients are relevant for MICU
patients is uncertain, but this evidence gives us a direction for
research in mechanisms and therapy.
Conclusion on prevention and treatment
The data to support a treatment strategy are insufficient in
MICU patients. Patient heterogeneity and spontaneous
conversion require randomised controlled trials against a
placebo. This trial evidence is not available, so we have to
use data from other patient groups. In these patients it
appears that electric conversion is not useful because of the
high relapse rate. Digoxin is not very effective for SR
conversion or rate control. Calcium antagonists are modestly
effective but have the serious adverse effect of inducting
hypotension. Class IA, class IIC and class III antiarrhythmic
drugs are effective but have a significant proarrhythmic effect.
The same observation holds true for ibutilide and propafenon.
Magnesium is safe and seems effective. Amiodarone is
effective but hypotension is seen, although not very
frequently. β-Blockers are effective in prevention but data on
treatment are less robust. Steroids and statins may prevent
AF in patients with a systemic inflammation.
Adverse effects of (preventive) treatment
Pharmacokinetics and pharmacodynamics are changed in
ICU patients [107]. Multiple drug use may cause drug
interactions [107]. These factors might render ICU patients
more prone to side effects [107,108]. There are limited data,
however, for MICU patients. Amiodarone-induced pulmonary
toxicity has been described in postmortem MICU patients
Critical Care    Vol 11 No 6 Sleeswijk et al.
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In surgical ICU patients, amiodarone induces hypotension
after intravenous loading [81,82]. Severe hepatoxicity due to
amiodarone has been described [111]. Ventricular
tachycardia occurred in CTS patients [80].
In non-ICU patients admitted for AF there is a high incidence
of adverse events, mainly cardiac, from antiarrhythmic drugs
[112]. On the other hand, the incidence of amiodarone-
induced proarrhythmic effects is low [113-115]. Nevertheless
amiodarone remains a drug with many side effects. Amiodarone
pulmonary toxicity, especially in the previously damaged lung,
is a hazardous adverse effect [108,110,116]. The occurrence
is probably cumulative, dose dependent and duration
dependent, but adverse pulmonary effects can also be seen
within 3 days after the start of administration [110,114,115].
Drug interactions might be more frequent for amiodarone but
have not extensively been studied [117]. The implications for
the ICU patient of the effect of amiodarone on thyroid gland
function, which is a major problem in outpatients, are not yet
clear [118,119]. Amiodarone has a complex pharmacokinetic
and pharmacodynamic profile [120].
Conclusion on adverse effects
Owing to the multiplicity of symptoms in ICU patients,
adverse effects can be easily overlooked or attributed to the
underlying disease. Reports on adverse effects of anti-
arrhythmic drugs have mainly been described in non-ICU
patients. The proarrhythmic effect is the most frequent and
serious side effect. Hypotension, however, is also an
important side effect described in ICU patients. An adverse
effect of a specific drug is hard to detect in ICU patients
because of the polypharmacy and because of the difficulty to
distinguish between adverse effects, underlying disease and
other nosocomial complications.
Can treatment of atrial fibrillation improve
survival?
There are few data on the effect of treatment of AF on mortality
in ICU patients. A meta-analysis in non-ICU patients showed
that class IA, class IC and class III antiarrhythmic agents are
equally effective in reaching SR. No impact, however, on the
quality of life or the mortality could be found [98]. β-Blockers
improve survival in patients with heart failure and AF [121].
Amiodarone treatment in patients with AF and congestive heart
failure improved conversion to SR and survival [122].
Conclusion on improvement of survival
There are no studies in ICU patients showing a survival
advantage in the treatment group; the advantage could either
not be shown or was not an endpoint of the study. In non-ICU
patients with heart failure and AF there is a survival advantage
for  β-blockers and amiodarone, which also has β-blocking
activity. This might be related to the well-known effect of β-
blockers on survival in patients with heart failure and not
because of rate control or rhythm control.
Can treatment of atrial fibrillation improve
morbidity?
There are no data on MICU patients. In a retrospective study
in surgical patients with new-onset supraventricular tachy-
cardia (93% with AF), continuous infusion of amiodarone did
not lead to significant differences in haemodynamics in
responders compared with nonresponders [77,123]. Another
retrospective study in a selected population of critically ill
patients showed that amiodarone improved haemodynamic
parameters compared with pretreatment values [42].
In a mixed ICU patient population, conversion to SR did not
increase the systolic blood pressure [73]. Most patients are
already haemodynamically unstable before AF, and the
contribution of AF is uncertain [124].
Conclusion on improvement of morbidity
The best available evidence comes from retrospective studies.
The impact of conversion to SR or control of rhythm on haemo-
dynamics is probably limited, although most clinicians intuitively
would state that haemodynamics improve with treatment.
Should we aim for rate control or rhythm
control?
There are no data in MICU patients. In a pilot trial in CTS
patients there was no difference in the LOS or rhythm at
discharge between rate control and rhythm control strategies
[125,126]. After cardiac surgery in haemodynamically stable
patients, rate control is preferred over rhythm control because
almost all patients convert spontaneously within 6 weeks
after surgery [12,86,125,127].
Five randomised-controlled trials in non-ICU patients did not
show a beneficial effect of rhythm control over rate control in
haemodynamically stable patients [128,129]. These studies
have been described in three meta-analyses; rate control
showed less adverse events and less hospitalisations
[9,89,130]. These meta-analyses, however, do not sufficiently
cover specific patient groups [124].
Conclusion on rate control or rhythm control
There are insufficient data in ICU patients to justify a choice
between therapy directed on rate control or on rhythm
control. Rhythm control clearly has no advantage above rate
control, as measured both by morbidity or mortality, in non-
ICU patients.
Does atrial fibrillation increase stroke
incidence in medical ICU patients?
There are no data on stroke incidence in the MICU. Short-term
postoperative AF is a risk factor for stroke in CTS patients
[131]. Postoperative AF doubles the risk compared with
patients without AF, despite the use of aspirin [22,32,131,132].
AF is an independent risk factor for stroke in non-ICU
patients [133]. In patients with AF, an inflammatory response
Available online http://ccforum.com/content/11/6/233
Page 5 of 10
(page number not for citation purposes)is an independent risk for stroke [134]. The prothrombotic
state due to inflammation is probably more important than the
presence of AF [25]. An increased C-reactive protein level is
a risk factor for thromboembolism in patients with AF [135].
Conclusion on stroke incidence
There are insufficient data in medical ICU patients, but in
CTS patients it is clear that the stroke incidence is increased
in patients with AF. Besides AF, a proinflammatory state is
also a risk factor.
Can stroke be prevented?
Since there are no data on stroke incidence in MICU patients,
there are also no data on prevention.
In elderly patients undergoing cardiothoracic surgery
receiving preventive treatment with amiodarone in addition to
β-blocker, the incidence of AF and stroke was significantly
reduced but the mortality was not changed [53]. This effect
was also shown in a meta-analysis [55].
The stroke incidence in non-ICU patients can be reduced
with anticoagulation. The bleeding risk is outweighed by the
advantage of a reduced stroke incidence in most patients [8].
There is no difference between rate control and rhythm
control in stroke incidence when the patient is on
anticoagulation treatment [130]. Treatment of the
proinflammatory state can reduce the incidence of stroke.
Conclusion on stroke prevention
The incidence of stroke can probably be reduced in ICU
patients with anticoagulation. There are no clear data that this
risk reduction outweighs the increased bleeding risk in these
patients. The proinflammatory state probably increases the
risk for stroke and the risk for AF independently [136].
Discussion
Although AF is a frequent symptom associated with a high
mortality in critically ill patients, there are still many lacunae in
our knowledge. We evaluated the actual level of knowledge
with the purpose to reach a treatment protocol based on best
available evidence. There is no literature, however, presenting
the criteria of evidence-based medicine. Even the questions
of whether AF is the cause of mortality or just an
epiphenomenon [3] and of whether treatment improves
outcome are still not answered. A treatment protocol
therefore has to be based on extrapolation of results from
studies performed in other patient groups. But even in these
patient groups, there is still a lot of debate about the optimal
treatment protocol [137].
Because the beneficial effect of treatment is not certain, any
protocol should at least not add serious adverse events; first,
do no harm. Doing as little as possible is a defendable credo.
This means optimising the fluid balance, correcting electro-
lyte disturbances, reducing sympaticus tonus and avoiding
proarrhythmic drugs. Reduction of the systemic inflammatory
state is tempting but is of course always the purpose of ICU
treatment. The evidence for the use of steroids for this
indication is insufficient. When the ventricular rate is arbitrarily
judged acceptable and there is little haemodynamic
compromise, no further action is probably required. If this
condition is not met, we have to seek the balance between
benefit and harm.
Direct-current cardioversion is not useful because of the high
relapse rate. In some situations, however, judged to be
desperate, direct-current cardioversion will be performed. It
has also not been proven that electrical cardioversion does
not damage a heart already involved in the multiorgan failure
of critical illness. Although the effectiveness of magnesium
has been questioned there are no reports on adverse effects.
In nonacutely threatened patients, therefore, an attempt to
achieve rate control and even rhythm control with intravenous
infusion of magnesium is worthwhile. If further treatment is
deemed necessary, a choice has to be made between
various antiarrhythmic drugs. Class IA, class IC and class III
antiarrhythmic drugs all are effective but are also pro-
arrhythmic. Calcium-channel blockers are less effective and
have the disadvantage of causing hypotension. Intensivists
may have an emotional barrier to using β-blockers in patients
also receiving vasopressors and inotropes, but β-blockers
could be a rational choice. The choice made by most
intensivists, however, is for amiodarone: this drug is effective,
although not as fast acting as some other drugs. The acute
adverse effects seem to be very limited, but the adverse
effects in the long term might be a problem. We therefore
advocate short-term use of amiodarone if treatment is
deemed necessary.
A protocol concerning AF should also have a statement
about stroke prevention. There are, however, no data to
support such a statement. We have no data on the stroke
incidence of medical ICU patients with AF. Owing to the
proinflammatory state, this incidence is probably higher than
in other patients with AF. On the other hand, there is also an
increased, but unquantified, bleeding risk. Risks and benefits
of anticoagulation can therefore not be weighed in general.
This balance has to be estimated for individual patients, and
an educated guess has to be made [136].
Conclusion
A rational treatment protocol could therefore consist of
several steps. First, treatment of predisposing factors is
necessary. Second, a short attempt at magnesium supple-
mentation can be done. Third, amiodarone can be adminis-
tered for a short-term period. Most patients will by then have
an acceptable rate or rhythm; however, if the patient does
not, ibutilide (a class III drug) can serve as rescue treatment.
We have treated 29 patients in a MICU with this protocol.
Ninety per cent of the patients had SR after 24 hours and all
Critical Care    Vol 11 No 6 Sleeswijk et al.
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use ibutilide treatment, nor direct-current cardioversion. The
inhospital mortality in this patient group, however, was still
38% [138].
Having a protocol with a reasonable success rate does not
release us from doing further research. The high mortality rate
could be caused by the fact that AF is just an epi-
phenomenon in critically ill patients. The possibility that the
mortality is in part caused by insufficient treatment of AF or,
on the contrary, is caused by adverse effects of the treatment,
however, is too realistic to be ignored. All we have stated
about the treatment of AF in MICU patients is based on
extrapolation and is therefore just a hypothesis. We should
therefore explore the possibility of randomised controlled
trials against placebo. These trials should be based on a
better understanding of AF in critically ill patients.
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